GB2450691A - One-pot preparation of oxycodone from thebaine - Google Patents
One-pot preparation of oxycodone from thebaine Download PDFInfo
- Publication number
- GB2450691A GB2450691A GB0712783A GB0712783A GB2450691A GB 2450691 A GB2450691 A GB 2450691A GB 0712783 A GB0712783 A GB 0712783A GB 0712783 A GB0712783 A GB 0712783A GB 2450691 A GB2450691 A GB 2450691A
- Authority
- GB
- United Kingdom
- Prior art keywords
- thebaine
- oxidation
- hydroxycodeinone
- reaction
- oxycodone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 229930003945 thebaine Natural products 0.000 title claims abstract description 41
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 title claims abstract description 41
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims abstract description 36
- 229960002085 oxycodone Drugs 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000005580 one pot reaction Methods 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 73
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 39
- YYCRAERBSFHMPL-XFKAJCMBSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 YYCRAERBSFHMPL-XFKAJCMBSA-N 0.000 claims abstract description 28
- YYCRAERBSFHMPL-UHFFFAOYSA-N 14beta-Hydroxycodeinone Natural products O1C2C(=O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YYCRAERBSFHMPL-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960000583 acetic acid Drugs 0.000 claims abstract description 25
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 24
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000003647 oxidation Effects 0.000 claims abstract description 23
- 238000006722 reduction reaction Methods 0.000 claims abstract description 20
- 150000002978 peroxides Chemical class 0.000 claims abstract description 15
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 13
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 12
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 8
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 238000002955 isolation Methods 0.000 claims abstract description 6
- 229910000564 Raney nickel Inorganic materials 0.000 claims abstract description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims abstract description 4
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 abstract description 4
- 239000007868 Raney catalyst Substances 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000002904 solvent Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- -1 organo silyl compound Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- PWSNDIVDQRUBKY-YYMROMDTSA-N (4R,4aR,7aR,12bS)-8a-hydroxy-9-methoxy-3-methyl-2,4,4a,7a,9,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound OC12C(C=CC=3C[C@@H]4[C@@H]5C=CC([C@@H]([C@@]5(C1=3)CCN4C)O2)=O)OC PWSNDIVDQRUBKY-YYMROMDTSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- XYYVYLMBEZUESM-CMKMFDCUSA-N codeinone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=CC(=O)[C@@H]1OC1=C2C3=CC=C1OC XYYVYLMBEZUESM-CMKMFDCUSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HNLHRDYYMDIPDE-IEGACIPQSA-N (4R,4aS,7aR,12bS)-4a,5-dihydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound OC1=CC([C@H]2[C@]34C=5C(=C(C=CC=5C[C@H]([C@]13O)N(C)CC4)OC)O2)=O HNLHRDYYMDIPDE-IEGACIPQSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- PDRNJKDODQMLSW-HZVMSULOSA-N N[C@@H](CCCNC(N)=N)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O.Nc1nc2[nH]cc(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c2c(=O)[nH]1 Chemical compound N[C@@H](CCCNC(N)=N)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O.Nc1nc2[nH]cc(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c2c(=O)[nH]1 PDRNJKDODQMLSW-HZVMSULOSA-N 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- CWIYRGHXIQNYHE-UHFFFAOYSA-L [Cr](=O)(=O)(O)O.[Cr](=O)(=O)([O-])[O-].[K+].[K+] Chemical compound [Cr](=O)(=O)(O)O.[Cr](=O)(=O)([O-])[O-].[K+].[K+] CWIYRGHXIQNYHE-UHFFFAOYSA-L 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- CZPZWMPYEINMCF-UHFFFAOYSA-N propaneperoxoic acid Chemical compound CCC(=O)OO CZPZWMPYEINMCF-UHFFFAOYSA-N 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A process for the large scale preparation of oxycodone from thebaine which comprises: <SL> <LI>(i) oxidation of thebaine to 14-hydroxycodeinone with a peroxide; and <LI>(ii) reduction of 14-hydroxycodeinone with hydrogen, characterised in that: <LI>(iii) the oxidation reaction is carried out on more than 50g of thebaine, and <LI>(iv) both the oxidation and reduction reactions are carried out in acetic acid or propionic acid; and <LI>(v) both the oxidation and reduction reactions are carried out in the same vessel without isolation of the 14-hydroxycodeinone; and <LI>(vi) the oxidation reaction is performed at a temperature below 35{C. </SL> Glacial acetic acid and hydrogen peroxide are preferably used in the oxidation reaction. Preferred catalysts for the hydrogenation include palladium on carbon (Pd/C), platinum dioxide and Raney nickel.
Description
I
PREPARATION OF OXYCODONE
This invention relates to a pharmaceutical process, specifically for the preparation of oxycodone from thebaine.
The following reaction sequence shows the conversion of thebaine to oxycodone via the intermediate I 4-hydroxycodeinone.
Hi4N Ox [iJ Tebaune 14-hydroxycoddnone Oycodoue in the oxidation step, the concomitant N-oxide of 14-hydroxycodeinone is also formed. However, this intermediate is reduced to the desired product during the subsequent reduction step.
15 Oxycodone and it's hydrochloride salt are analgesics and are useful S... . . . intermediates for use in the production of other commercial and well known morphinans, including naltrexone and naloxone, which are shown below. S..
I 5* SI * S I * .
I **.
S
NALTREXONE HO NALMEFENE \
H
NALBUPKrNE
NALOXONE NALORPHINE
Oxycodone has been known for over 30 years and numerous reaction sequences are known for its preparation. Some known sequences for preparing oxycodone from thebaine are discussed below. 0**
International Patent Application No PCT/SK2005/000014 (Zentiva, A.S.), discloses a method for the preparation of oxycodone from thebaine which is . carried out in two steps. The first step is to react thebaine with hydrogen peroxide or peroxoacids in the presence of oxalic acid and another organic acid such as formic acid or acetic acid to produce 14-dihydroxycodeinone * oxalate. 14-hydroxycodeinone is then isolated after addition of a base. The second step is to hydrogenate the l4-hydroxycodeinone with hydrogen in the presence of a catalyst to yield oxycodone. This international patent application describes a two-step process, each step being carried out in different solvents and in different vessels. It also describes the presence of oxalic acid being an essential element in the reaction.
US Patent No 6,262,266B (Boehringer Ingeiheim Chemicals mc) describes a method for the synthesis of oxycodone from codeine by first oxidising codeine to codeinone followed by protection of codeinone using an organo silyl compound to produce a dienol silyl ether derivative. The next step is an oxidation of the dienol silyl ether derivative of codeinone to produce 14-hydroxycodeinone, which in a further step is reduced by a catalytic hydrogen transfer method to produce oxycodone. The process described in US 6,262,266 is carried out in more than one step and each step is carried out in a different reaction vessel. Furthermore, US 6,262,266 teaches the necessity to use organo silyl compounds as protecting groups whereas this protecting step is not required by the present invention.
US Patent No 7,153,966 B (Johnson Matthey Public Limited) describes a method for the preparation of oxycodone from thebaine having low levels of impurities, such as 14-hydroxycodejnone. Two processes are exemplified in the patent. In the first process, formic acid and hydrogen peroxide is added to a solution of thebaine in water to produce 14-hydroxycodeinone. The 14-hydroxycodeinone is then transferred to a hydrogenation bottle, a palladium on carbon catalyst is added and hydrogen is passed through the mixture :. 20 resulting in the production of oxycodone In the second process hydrogen peroxide is added to thebaine dissolved in formic acid. 14-*.S.
hydroxycodeinone is isolated as a precipitate by the addition of ammonium hydroxide solution. The 14-hydroxycodejnone is then hydrogenated by passing hydrogen through a mixture of acetic acid and 14-hydroxycodeinone dissolved in water. Neither of the processes described are one-step : processes", performed in the same vessel without isolation and in the same solvent (e.g. acetic acid) from the beginning of the process to the end.
US Patent Application No. 10/892,578 (US 2005/0038251) (Francis et a!) describes a small scale process for the preparation of oxycodone comprising the oxidation of thebaine to 14-hydroxycodeinone followed by reduction of the 14-hydroxycodeinone to oxycodone by hydrogenation. The processes described in this US application are not for large-scale preparation of oxycodone or wherein the oxidation reaction is performed at a temperature of below 35 C as in the present invention.
US Patent Application No. 11/391,897 (US 2006/01 73029) (Chapman eta!) describes a small scale process for the preparation of oxycodone from thebaine in three steps. The first of the three steps is an oxidation reaction followed by two hydrogenation reactions via a 8,14-dihydroxy-7,8-dihydrocodeinone intermediate. This US patent application does describe a process which can be performed on a large scale and can be carried out in one step, in the same solvent and without isolation of the intermediates.
Unfortunately, as can be seen from the above, known reaction sequences typically involve a number of steps (sometimes involving further protection steps) and have low overall yields. In addition, known reaction sequences often produce an undesired amount of a mutagenic by-product, 14-hydroxy-codeinone. Currently, the amount of 14-hydroxycodeinone allowed in the final product for administration is strictly regulated, varying from 10-150 ppm depending on the size of dosage administered to the patient. I. * * * ***
***. 0 H3C o,, I 4-hydroxycodeinone It is desirable to find a method for producing oxycodone from thebaine which can be carried out in fewer steps, preferably in one step, and further preferably in the same "pot" and without the change of solvent.
It is also desirable to find a method for producing oxycodone from thebaine which does not involve the need to protect intermediates.
It is also desirable to find a method for producing oxycodone from thebaine which can be performed under ambient conditions.
Furthermore it is desirable to find a method which produces fewer impurities, such as the mutagenic 14-hydroxycodeinone and higher yields than current processes.
A skilled person in the pharmaceutical manufacturing industry would appreciate that scaling-up the amounts of reagents used in manufacturing processes from lab-sized scale does not always work. Many problems are involved in increasing the scale of industrial processes, such as,. for example, inefficient heat transfer throughout vessels, inefficient mixing of reagents and lack of control when changing temperature. These difficulties may lead to, a reduction in overall yields and lower purities of the final products of large scale processes.
:. 20 It is therefore also desirable to find a large scale method for processing oxycodone from thebaine which can be carried out in one step. Preferably S...
the large scale method could be carried out in the same pot, without a change in solvent and would produce oxycodone in excellent yields. It would also be desirable to find a large scale method for producing oxycodone from thebairie in which the oxycodone product contains low : levels of impurities. S..
S
There is provided a method for producing oxycodone from thebaine which overcomes many of the disadvantages of the prior art noted above.
The present invention provides a process for the large scale preparation of oxycodone from thebaine which comprises (i) oxidation of thebaine to 14-hydroxycodeinone with a peroxide; and (ii) reduction of 14-hydroxycodeinone with hydrogen, characterised in that: (iii) the oxidation reaction is carried out on more than 50g of thebaine, and (iv) both the oxidation and reduction reactions are carried out in acetic acid or propionic acid; and (v) both the oxidation and reduction reactions are carried out in the same vessel without isolation of the 14-hydroxycodeinone; and (vi) the oxidation reaction is performed at a temperature below 35 C.
The oxidation reaction is effected by addition of acetic acid or propionic acid in combination with the peroxide. The acetic acid or propionic acids act as solvents as well as peroxy acid precursors. The addition of acetic acid or propionic acid results in the formation of peracetic acid or perpropionic acid oxidation reagents in-situ. It has been found that acetic acid, preferably in the form of glacial acetic acid, results in a higher degree of conversion from *1S** thebaine to 14-hydroxycocjeinone and N-oxides thereof than if propionic acid I...
is used. For example, if glacial acetic acid is used, about 95% of the 14-hydroxycodeinone and its N-oxide is typically obtained. When propionic acid is used, conversions of greater than 90 % of 14-hydroxycodeinone and its N-oxide are typically obtained.
Suitably, the peroxide used in the oxidation reaction is hydrogen peroxide.
It was surprisingly noted during optimisation of the oxidation reaction that the use of formic acid (as taught in US Patent No 7,153, 966, GB939287 and US6090943) instead of acetic acid or propionic acid results in complete degradation of thebaine. The use of glacial acetic acid or propionic acid therefore leads to higher yields than if formic acid is used.
Furthermore, it has also been found that an acidified aqueous solution of potassium chromate (chromic acid) as the oxidation reagent did not result in an appropriate oxidation of thebaine.
Hydrogen peroxide may be added to the reaction mixture in more than one aliquot. For example it may be added in 2 or 3 aUquots.
The ratio of thebaine to carboxylic acid (acetic acid or propionic acid) and peroxide in the oxidation reaction effects the purity and yield of the oxidation products (14-hydroxycodienone and its N-oxide) as well as the reaction rate.
The preferred ratio of thebaine to carboxylic acid to peroxide was found to be about Ig thebaine: 8m1 carboxylic acid: 2m1 peroxide, i.e. Ig thebaine: 8ml acetic acid: 2m1 hydrogen peroxide. This ratio between the reagents resulted in the highest yield of intermediates obtained (about 95%, monitored by HPLC). When the ratio of thebaine to carboxylic acid was changed to Ig thebaine to 4ml carboxylic acid (i.e. acetic acid) and 2m1 of peroxide (i.e. hydrogen peroxide), the yield of oxidation products is reduced to about 60%. Additionally, when the ratio of thebaine to carboxylic acid was changed to Ig thebaine to l6ml of carboxylic acid (i.e. acetic acid) and 2mI of peroxide (i.e. hydrogen peroxide), the yield of the oxidation products is reduced to about 93%, i.e. it had a negative effect on the impurity profile of **S.
the reaction. I. * * * I**
The oxidation reaction may be performed at ambient temperature (i.e. between 15 C-30 C or preferably between 20 C-25 C). Suitably, the peroxide which is at a depressed temperature (i.e. about 00C-5 C) is added to the reaction mixture which is at an ambient temperature (i.e. between 15 C-30 C). By lowering the temperature, the overoxidation to e.g. the 8, 14-dihydroxycodeinone is suppressed, leading to an improved impurity profile. Typically this is achieved by cooling the reaction mixture towards the end of the oxidation step (i.e. to about O C-5 C) and halting the oxidation before all of the substrate has been consumed.
The oxidation reaction may take between 2 and 24 hours, 4 and 24 hours, 4 and 21 hours, 8 and 21 hours, 8 and 16 hours, 8 and 12 hours, 8 and 10 hours, 10 and 12 hours or 12 to 18 hours to complete. Suitably the reaction takes between 16-21 hours to complete at 23 C.
The reduction reaction is carried out in the same vessel without isolation of the 14-hydroxycodeinone and its concomitant N-oxide.
The reduction reaction is effected by addition of a catalyst and hydrogen gas to the reaction mixture. Suitable catalysts include Palladium on carbon (Pd/C), platinum dioxide catalyst (Pt02, e.g. Pt02 type D) and Raney nickel.
The preferred catalyst is palladium on carbon. The use of Pd/activated charcoal results in higher yields and less by-product formation than if Pt02 or Raney nickel are used.
The hydrogen gas is added at a pressure of between 1-5 bar, 2-4 bar or about 3 bar. Preferably, hydrogen gas is added at a pressure of about 3 bar.
The reduction reaction is performed at a temperature between -5 C -30 C or :. 20 -5 C-25 C. When conducted at a depressed temperature (i.e. -5 C -5 C), :..::: the reaction may take up to 100 hours to go to completion. Whereas at I** ambient temperature (i.e. 20 C -25 C), the reaction is complete after 30 hours. S..
By carrying out the oxidation and reduction reactions in the manner * discussed above, it is possible to produce oxycodone free base in a large *5* scale process from thebaine in one reaction vessel and without the change of solvent. Furthermore both the oxidation and reduction reactions can be performed under ambient conditions, yielding, less impurities, such as the mutagenic 14-hydroxycodeinone. The final yields of oxycodone are typically in the range of 87-95 % with a purity of 93%. Further, recrystallisation of the isolated crude product results in a purity of oxycodone typically being greater than 98%. The overall yield of the process is normally in the range of 71-78 %. r
The invention is illustrated by the examples below.
Example I
A 2L reactor charged with glacial acetic acid (1L) was added fine grained thebaine (125 g) in one portion at ambient temperature. After -60 mm. a clear and pale yellow solution was obtained. The roomtemperated reaction mixture was quickly added (in one portion) an ice-cold 30% aqueous solution of H202 (250 ml). HPLC (Ph. Eur.) after 16 hours showed two main peaks, the expected product (73 %) and the N-oxide of 14-hydroxycodeinone (21 %) i.e. an reaction yield of -94 %. About 2.5 % of the starting material was left unconsumed. The temperature was lowered to 10 C before Pd/C (6 g) was added in one portion. The reactor was left for venting in about 1 hour before the temperature was raised to 23 C and left for another hour. When the gas evolution had ceased the reactor was flushed with nitrogen 4 times before a H2 pressure of -45 psi (3 bars) was applied to the reactor. Reaction over-night showed a complete conversion of the intermediates to oxycodone as confirmed by HPLC (Ph. Eur.). The reaction mixture was filtered through a bed of celite following a removal of 20 the solvent (750 ml) by reduced pressure. The removed solvent was *::::* replaced (by addition of 750 ml water) before quenching with 50 % NaOH (800 ml) to a heavy precipitation. The mixture was filtered, the filter cake * : was washed with water (1 L) and dried in a vacuum oven at 60 C yielding **.
* oxycodone (free base) 110 g (87 %) with a purity of 93 % by HPLC (Ph.
p.'. 25 Eur.). 27 g of the isolated crude product was recrystallised by EtOH:H20 80:20 (made up of 400 ml rect. ethanol (EtOH:MeOH 95:5) and 100 ml water) yielding oxycodone free base (22 g, 82 %) with a HPLC purity of >98 %.
Example 2
A 2L reactor charged with glacial acetic acid (0.64 L) was added fine grained thebaine (80 g) in one portion at 20 C. After -60 mm. a clear and pale yellow solution was obtained. The roomtemperated reaction mixture was quickly added (in one portion) an ice-cold 30% aqueous solution of H202 (160 ml). After about 14 hours the temperature was increased to 23 C.
HPLC (Ph. Eur.) after a total reaction time of about 20 hours showed two main peaks giving a total reaction yield of -90 % of 14-hydroxycodeinone' and the concomitant N-oxide). 4 % of the starting material was left unconsumed. The reaction temperature was lowered to -1 CC before Pd/C (6 g) was added in one portion. The reactor was left stirring for 21 h, was flushed with nitrogen 4 times before a H2 pressure of -3 bar was applied to the reaction vessel. Monitoring the reaction by HPLC (Ph. Eur) after 80 hours showed a complete conversion of the two main intermediates from the oxidation part of the process, to oxycodone. The reaction mixture was filtered through a bed of celite following a removal of the solvent (750 ml) by reduced pressure. The removed solvent was replaced (by addition of 750 ml water) before quenching with 50% NaOH (800 ml) to a heavy precipitation.
The mixture was filtered, the filter cake was washed with water (1 L) and dried in a vacuum oven at 60 C yielding 77.5 g (95 %) of crude oxycodone (free base) with a purity of 93% by the Ph. Eur. HPLC method. S. * S.. * * S... S. * * * SS*
S S..
S S. ** * . S *.S
Claims (11)
- Claims 1. A process for the large scale preparation of oxycodone fromthebaine which comprises:- (i) oxidation of thebaine to 14-hydroxycodeinone with a peroxide; and (ii) reduction of 14-hydroxycodeinone with hydrogen, characterised in that: (iii) the oxidation reaction is carried out on more than 50g of thebaine, and (iv) both the oxidation and reduction reactions are carried out in acetic acid or propionic acid; and (v) both the oxidation and reduction reactions are carried out in the same vessel without isolation of the 14-hydroxycodeinone; and (vi) the oxidation reaction is performed at a temperature below 35 C.
- 2. A process as claimed in Claim 1, wherein the oxidation reaction also produces intermediate N-oxides of 14-hydroxycodeinone, which are subsequently reduced in the reduction reaction.
- 3. A process as claimed in Claim 1 or Claim 2 wherein the oxidation reaction is effected by addition of acetic acid, preferably glacial acetic acid. *, S * * * S..
- 4. A process as claimed in Claims 2 or 3 wherein the hydrogen peroxide is added in one or more aliquots, for example 2 or 3 aliquots.
- 5. A process as claimed in Claims I to 4 wherein the oxidation reaction is performed at 15 C to 30 C or at 20 C to 25 C.
- 6. A process as claimed in any preceding claim wherein the peroxide is hydrogen peroxide.
- 7. A process as claimed in any preceding claim wherein the reduction reaction is effected by addition of hydrogen gas and a catalyst, such as a palladium on carbon catalyst, a platinum dioxide catalyst or a Raney nickel catalyst, preferably a palladium on carbon catalyst (Pd/C).
- 8. A process as claimed in Claim 7 wherein the reduction reaction is performed between -5 C to 30 C or 0 C to 25 C..
- 9. A process as claimed in Claims 7 and 8 wherein the hydrogen gas is added at a pressure of between I to 5 bar or 2 to 4 bar or about 3 bar, preferably at about 3 bar.
- 10. A process as claimed in any preceding claim wherein the ratio of thebaine to peroxide and acetic/propionic acid is the same as I g thebaine: 8mL acetic/propionic acid: 2mL peroxide.
- 11. A process as claimed in claim 10 wherein the peroxide is hydrogen peroxide and the acetic acid is glacial acetic acid. *,.. * * I0. * * * S* *.* S. SI I. S * SI S..S
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0712783A GB2450691A (en) | 2007-07-02 | 2007-07-02 | One-pot preparation of oxycodone from thebaine |
PCT/IB2008/002610 WO2009004491A2 (en) | 2007-07-02 | 2008-06-25 | Preparation of oxycodone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0712783A GB2450691A (en) | 2007-07-02 | 2007-07-02 | One-pot preparation of oxycodone from thebaine |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0712783D0 GB0712783D0 (en) | 2007-08-08 |
GB2450691A true GB2450691A (en) | 2009-01-07 |
Family
ID=38421057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0712783A Withdrawn GB2450691A (en) | 2007-07-02 | 2007-07-02 | One-pot preparation of oxycodone from thebaine |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2450691A (en) |
WO (1) | WO2009004491A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815289B2 (en) | 2006-08-25 | 2014-08-26 | Purdue Pharma L.P. | Tamper resistant dosage forms |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI483944B (en) | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone |
JP5824448B2 (en) | 2009-04-24 | 2015-11-25 | ブロック ユニバーシティ | Preparation of morphinan and morphinone compounds |
EP2377866B1 (en) | 2010-03-23 | 2014-02-26 | Siegfried AG | Preparation of low impurity opiates in a continuous flow reactor |
CA2879268C (en) | 2012-07-16 | 2018-05-08 | Rhodes Technologies | Process for improved opioid synthesis |
CA2880446C (en) | 2012-08-03 | 2018-03-13 | Johnson Matthey Public Limited Company | A method for preparing oxycodone |
US10227354B2 (en) | 2013-12-18 | 2019-03-12 | Cody Laboratories, Inc. | Conversion of oxycodone base to oxycodone hydrochloride |
US8846923B1 (en) | 2013-12-18 | 2014-09-30 | Cody Laboratories, Inc. | Preparation of 14-hydroxycodeinone sulfate |
US9062062B1 (en) | 2013-12-18 | 2015-06-23 | Cody Laboratories, Inc. | Synthesis of oxycodone hydrochloride |
AU2015207733A1 (en) * | 2014-01-15 | 2016-07-14 | Rhodes Technologies | Process for improved oxycodone synthesis |
EP3642207B1 (en) * | 2017-06-20 | 2022-08-31 | Johnson Matthey Public Limited Company | Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112975A (en) * | 1984-03-27 | 1992-05-12 | Mallinckrodt Specialty Chemicals Company | Preparation of noroxymorphone from morphine |
US20050038251A1 (en) * | 2003-06-05 | 2005-02-17 | Francis Charles Auxilium | Process for manufacturing opioid analgesics |
WO2006138020A2 (en) * | 2005-06-16 | 2006-12-28 | Mallinckrodt Inc. | A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10325413B4 (en) * | 2003-06-05 | 2015-03-05 | Audi Ag | Method for operating an internal combustion engine of a vehicle, in particular a Kraftfahtzeuges and apparatus for performing such a method |
SK286087B6 (en) * | 2004-08-18 | 2008-03-05 | Zentiva, A. S. | Method of preparation of oxycodone |
-
2007
- 2007-07-02 GB GB0712783A patent/GB2450691A/en not_active Withdrawn
-
2008
- 2008-06-25 WO PCT/IB2008/002610 patent/WO2009004491A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112975A (en) * | 1984-03-27 | 1992-05-12 | Mallinckrodt Specialty Chemicals Company | Preparation of noroxymorphone from morphine |
US20050038251A1 (en) * | 2003-06-05 | 2005-02-17 | Francis Charles Auxilium | Process for manufacturing opioid analgesics |
WO2006138020A2 (en) * | 2005-06-16 | 2006-12-28 | Mallinckrodt Inc. | A synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs |
Non-Patent Citations (1)
Title |
---|
Arch. Pharm. Pharm. Med. Chem., Vol. 329, 1996, R. KRASSNIG et al, "Optimization of the synthesis of oxycodone and 5-methyloxycodone", pages 325-326 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815289B2 (en) | 2006-08-25 | 2014-08-26 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8821929B2 (en) | 2006-08-25 | 2014-09-02 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8834925B2 (en) | 2006-08-25 | 2014-09-16 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8846086B2 (en) | 2006-08-25 | 2014-09-30 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8894987B2 (en) | 2006-08-25 | 2014-11-25 | William H. McKenna | Tamper resistant dosage forms |
US8894988B2 (en) | 2006-08-25 | 2014-11-25 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8911719B2 (en) | 2006-08-25 | 2014-12-16 | Purdue Pharma Lp | Tamper resistant dosage forms |
US9084816B2 (en) | 2006-08-25 | 2015-07-21 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9095614B2 (en) | 2006-08-25 | 2015-08-04 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9095615B2 (en) | 2006-08-25 | 2015-08-04 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9101661B2 (en) | 2006-08-25 | 2015-08-11 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9486412B2 (en) | 2006-08-25 | 2016-11-08 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9486413B2 (en) | 2006-08-25 | 2016-11-08 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492393B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492391B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492389B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492390B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492392B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9545380B2 (en) | 2006-08-25 | 2017-01-17 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9763933B2 (en) | 2006-08-25 | 2017-09-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9763886B2 (en) | 2006-08-25 | 2017-09-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9770417B2 (en) | 2006-08-25 | 2017-09-26 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9770416B2 (en) | 2006-08-25 | 2017-09-26 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775812B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775809B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775808B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775810B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775811B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US10076498B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US10076499B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11298322B2 (en) | 2006-08-25 | 2022-04-12 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11304909B2 (en) | 2006-08-25 | 2022-04-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11304908B2 (en) | 2006-08-25 | 2022-04-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11826472B2 (en) | 2006-08-25 | 2023-11-28 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11904055B2 (en) | 2006-08-25 | 2024-02-20 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11938225B2 (en) | 2006-08-25 | 2024-03-26 | Purdue Pharm L.P. | Tamper resistant dosage forms |
US11964056B1 (en) | 2006-08-25 | 2024-04-23 | Purdue Pharma L.P | Tamper resistant dosage forms |
Also Published As
Publication number | Publication date |
---|---|
WO2009004491A3 (en) | 2009-04-02 |
WO2009004491A2 (en) | 2009-01-08 |
GB0712783D0 (en) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2450691A (en) | One-pot preparation of oxycodone from thebaine | |
EP2377866B1 (en) | Preparation of low impurity opiates in a continuous flow reactor | |
US7071336B2 (en) | Process for manufacturing opioid analgesics | |
EP2125824B1 (en) | Improved preparation of oxymorphone from oripavine | |
US8134002B2 (en) | Process for preparing oxymorphone | |
EP2332409B1 (en) | Process for preparing oxymorphone, naltrexone and buprenorphine | |
JP2008530036A (en) | Method for purifying noroxymorphone compounds | |
CA2684458A1 (en) | Novel opiate reduction utilizing catalytic hydrogen transfer reaction | |
EP1658293B1 (en) | A method of preparation of oxycodone | |
EP1664061B1 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
AU2002331163B2 (en) | Process for the Preparation of a 14-hydroxynormorphinone Compound | |
AU2002331163A1 (en) | Process for the Preparation of a 14-hydroxynormorphinone Compound | |
CN106083774B (en) | Process for producing gamma-butyrolactone | |
JP5376532B2 (en) | Method for producing camptothecin derivative | |
CA2591894C (en) | Process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanon2-yl)methyl] piperidine or its salt thereof via novel intermediate | |
AU2004274038B2 (en) | Process for the synthesis of morphinane compounds and intermediates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
COOA | Change in applicant's name or ownership of the application | ||
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |